TLIS
Closed
Talis Biomedical Corp
1.55
+0.09 (+6.16%)
Last Update: 06 Sep 2024 22:57:00
Yesterday: 1.46
Day's Range: 1.45 - 1.84
Send
sign up or login to leave a comment!
When Written:
0.4711
Talis Biomedical Corp is a private biotechnology company that develops and commercializes diagnostic tests for infectious diseases. The company was founded in 2018 and is headquartered in Menlo Park, California.
Talis Biomedical Corp has developed a proprietary technology platform called the Talis One system, which enables rapid and accurate diagnosis of infectious diseases at the point of care. The system uses a small disposable cartridge that contains all the necessary reagents and sensors to detect the presence of a pathogen in a patient sample. The cartridge is inserted into a handheld device that analyzes the sample and provides results within 30 minutes.
The company's initial focus is on developing tests for respiratory infections, including influenza and COVID-19. In response to the COVID-19 pandemic, Talis Biomedical Corp received emergency use authorization from the US Food and Drug Administration for its Talis One COVID-19 test in December 2020. The test is designed to detect the presence of the SARS-CoV-2 virus in nasal swab samples and provides results in 30 minutes.
Talis Biomedical Corp has raised over $100 million in funding from investors, including Menlo Ventures, Foresite Capital, and Illumina Ventures. The company has also formed partnerships with other companies and organizations, including the Bill and Melinda Gates Foundation and the US Department of Defense.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Talis Biomedical Corp has developed a proprietary technology platform called the Talis One system, which enables rapid and accurate diagnosis of infectious diseases at the point of care. The system uses a small disposable cartridge that contains all the necessary reagents and sensors to detect the presence of a pathogen in a patient sample. The cartridge is inserted into a handheld device that analyzes the sample and provides results within 30 minutes.
The company's initial focus is on developing tests for respiratory infections, including influenza and COVID-19. In response to the COVID-19 pandemic, Talis Biomedical Corp received emergency use authorization from the US Food and Drug Administration for its Talis One COVID-19 test in December 2020. The test is designed to detect the presence of the SARS-CoV-2 virus in nasal swab samples and provides results in 30 minutes.
Talis Biomedical Corp has raised over $100 million in funding from investors, including Menlo Ventures, Foresite Capital, and Illumina Ventures. The company has also formed partnerships with other companies and organizations, including the Bill and Melinda Gates Foundation and the US Department of Defense.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!